Harpoon Therapeutics and AbbVie entered an exclusive worldwide option and license agreement for HPN217, a BCMA-targeting TriTAC for multiple myeloma, and expanded their TriTAC discovery collaboration. Harpoon received $50M upfront with up to $510M in total upfront, option exercise and milestone payments plus royalties. AbbVie terminated the HPN217 option in 2022.